Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BPX-601 + Rimiducid|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BPX-601||GoCART BPX-601|iMC/PSCA-zeta BPX 601|Autologous PSCA CAR T Cells BPX-601||BPX-601 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting human prostate stem cell antigen (PSCA) and the zeta chain of the T-cell receptor (TCRzeta), and a rimiducid-induced co-stimulatory molecule, which activates anti-tumor immune response (PMID: 27824842).|
|Rimiducid||AP1903|AP-1903|AP 1903||Rimiducid is a tacrolimus analogue drug that contains an analogue of FKBP12, which allows homodimerization of genetically engineered receptors containing an FKBP12 binding domain, thereby, inducing apoptosis when necessary (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02744287||Phase Ib/II||BPX-601 + Rimiducid||Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors||Recruiting||USA||0|